Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Lapatinib, Trastuzumab, Endocrine; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions: lapatinib ditosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Metastatic Colorectal Cancer
Interventions: lapatinib, Capecitabine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Neoplasms, Breast
Interventions: Lapatinib in combination with an anti-cancer agent, Lapatinib, Lapatinib in combination with an anti-cancer agent as specified by parent protocol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 15
States / cities: Scottsdale, Arizona • Tucson, Arizona • Santa Monica, California + 12 more

Conditions: Malignant Melanoma
Interventions: Lapatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms, Gastrointestinal Tract
Interventions: Lapatinib, Placebo, Capecitabine, Oxaliplatin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 10
States / cities: Alhambra, California • Fullerton, California • La Verne, California + 7 more

Conditions: Breast Cancer
Interventions: lapatinib ditosylate, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, cell sorting, immunohistochemistry staining method, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 9
States / cities: Cleveland, Ohio

Conditions: Neoplasms, Breast
Interventions: lapatinib, Digoxin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Neoplasms, Breast
Interventions: lapatinib + capecitabine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 159
States / cities: Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 135 more

Conditions: Ovarian Cancer
Interventions: Lapatinib and Paclitaxel; Drug
Lead sponsor: Frederick R. Ueland, M.D.; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Cancer, Breast Neoplasms, Breast Tumors, Cancer, Locally Recurrent and Metastatic Breast Cancer, Metastases, Metastatic Cancer, Oncology, Solid Tumors, Tumors
Interventions: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab, AMG 386 10 mg/kg, Capecitabine and Lapatinib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 13
States / cities: Tucson, Arizona • Boca Raton, Florida • Iowa City, Iowa + 9 more

Conditions: HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Capecitabine, Cixutumumab, Lapatinib Ditosylate, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 390
States / cities: Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 274 more

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Trastuzumab, Aromatase Inhibitor; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 4
States / cities: Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more

Conditions: Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions: 75 approved agents, COXEN; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tamoxifen Citrate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions: Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: lapatinib ditosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neoplasms, Breast
Interventions: Trastuzumab, Paclitaxel, FEC75, Lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more

Conditions: Breast Neoplasms
Interventions: lapatinib, BIBW 2992, trastuzumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
Interventions: lapatinib ditosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HER2-Positive Early Stage Breast Cancer
Interventions: Paclitaxel, Trastuzumab, Lapatinib, Pegfilgrastim; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 1 more

Conditions: Breast Neoplasms
Interventions: Trastuzumab, pertuzumab, lapatinib; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Boston, Massachusetts + 2 more

Conditions: Breast Cancer
Interventions: LBH589, Capecitabine, Lapatinib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel, Trastuzumab; Other · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 317
States / cities: Tucson, Arizona • Fort Smith, Arkansas • Burbank, California + 222 more

Search by objective public record fields.

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Lapatinib in Stage IV Melanoma With ERBB4 Mutations

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Lapatinib Resistance in Patients With Breast Cancer

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery